Complete elimination of established neuroblastoma by synergistic action of γ-irradiation and DCs treated with rSeV expressing interferon-β gene

Gene Therapy

Volumn 16, Issue 2, 2009, Pages 240-251

  Tatsuta, K ^a   Tanaka, S ^a   Tajiri, T ^a   Shibata, S ^a,b   Komaru, A ^c   Ueda, Y ^c   Inoue, M ^d   Hasegawa, M ^d   Suita, S ^e   Sueishi, K ^a   Taguchi, T ^a   Yonemitsu, Y ^b,d  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d DNAVEC Corporation   (Japan)

^e FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL BASED GENE THERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GAMMA IRRADIATION; GENE EXPRESSION REGULATION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SENDAI VIRUS; SENSITIVITY ANALYSIS; SURVIVAL RATE; TRANSGENE; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNITY; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; A J MOUSE; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GAMMA RADIATION; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; THERAPEUTIC USE; TRANSPLANTATION;

ANIMALS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GAMMA RAYS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTERFERON-BETA; MICE; MICE, INBRED A; NEUROBLASTOMA; SENDAI VIRUS; GENETIC THERAPY;

MURINAE; MUS; SENDAI VIRUS;

EID: 60449114963     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.161     Document Type: Article

References (33)

1. Henry MC, Tashjian DB, Breuer CK. Neuroblastoma update. Curr Opin Oncol 2005; 17: 19-23.
2. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
3. Suita S, Tajiri T, Kaneko M, Hirai M, Mugishima H, Sugimoto T et al Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy. J Pediatr Surg 2007; 42: 489-493.
4. Suita S, Tajiri T, Sera Y, Takamatsu H, Mizote H, Nagasaki A et al Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification. J Pediatr Surg 2000; 35: 1737-1741.
5. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61: 8513-8519.
6. Caruso DA, Orme LM, Amor GM, Neale AM, Radcliff FJ, Downie P et al Results of a phase I study utilizing monocytederived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer 2005; 103: 1280-1291.
7. Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P et al. Immunogenicity of human neuroblastoma. Ann NY Acad Sci 2004; 1028: 69-80.
8. Sugio K, Nakagawara A, Sasazuki T. Association of expression between N-myc gene and MHC class I gene in surgically resected human neuroblastoma. Cancer 1991; 67: 1384-1388.
9. van't Veer LJ, Beijersbergen RL, Bernards R. N-myc suppresses MHC class I gene expression through down-regulation of the p50 subunit of NF-κB. EMBO J 1993; 12: 195-200.
10. Murphy C, Nikodem D, Howcroft K, Weissman JD, Singer DS. Active repression of major histocompatibility complex class I genes in a human neuroblastoma cell line. J Biol Chem 1996; 271: 30992-30999.
11. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE et al Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113: 1515-1525.
12. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10: 909-915.
13. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
14. Shibata S, Okano S, Yonemitsu Y, Onimaru M, Sata S, Nagata-Takeshita H et al. Induction of efficient antitumor immunity using dendritic cells activated by Sendai virus and its modulation of exogenous interferon-β gene. J Immunol 2006; 177: 3564-3576.
15. Yoneyama Y, Ueda Y, Akutsu Y, Matsunaga A, Shimada H, Kato T et al Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells. Biochem Biophys Res Commun 2007; 355: 129-135.
16. Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Dian J et al. Efficient gene transfer to the airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18: 970-973.
17. Masaki I, Yonemitsu Y, Komori K, Ueno H, Nakashima Y, Nakagawa K et al. Recombinant Sendai Virus-mediated gene transfer to vasculature: A new class of efficient gene transfer vector to the vascular system. FASEB J 2001; 15: 1294-1296.
18. Tanaka S, Yonemitsu Y, Yoshida K, Okano S, Kondo H, Inoue M et al. Impact of deletion of envelope-related genes of recombinant Sendai viruses on immune responses following pulmonary gene transfer of neonatal mice. Gene Therapy 2007; 14: 1017-1028.
19. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-737.
20. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K et al Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101-105.
21. Inoue M, Tokusumi Y, Ban H, Kanaya T, Shirakura M, Tokusumi T et al Nontransmissible virus-like particle formation by F-deficient Sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. J Virol 2003; 77: 3238-3246.
22. Inoue M, Tokusumi Y, Ban H, Kato A, Nagai Y, Iida A et al. Further attenuation of gene(s)-deleted Sendai virus vectors: Modification of transcription and replication caused weakened cytotoxicity. Mol Ther 2003; 7 (Suppl): S37 (abstract).
23. Ohba K, Omagari K, Nakamura T, Ikuno N, Saeki S, Matsuo I et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998; 43: 575-577.
24. Nam SW, Han JY, Kim JI, Park SH, Cho SH, Han NI et al. Spontaneous regression of a large hepatocellular carcinoma with skull metastasis. J Gastroenterol Hepatol 2005; 20: 488-492.
25. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862-870.
26. Watanabe I, Kurosawa N, Nishihira T. Establishment and characterization of a murine cell-line derived from malignant fibrous histiocytoma of A/ Jackson mouse. Tohoku J Exp Med 1998; 184: 173-187.
27. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B et al Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-58.
28. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells. Nat Med 1998; 4: 328-332.
29. Bhardwaj N. Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 2001; 7: 388-394.
30. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423-434.
31. Hong JH, Chiang CS, Campbell IL, Sun JR, Withers HR, McBride WH. Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys 1995; 33: 619-626.
32. Quarmby S, Kumar P, Kumar S. Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte endothelial cell interactions. Int J Cancer 1999; 82: 385-395.
33. Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer Treat Rev 2005; 31 159-172.